Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Memantine Hydrochloride Tablets USP, 5 mg and 10 mg. Memantine Hydrochloride Tablets are indicated for the treatment of moderate to severe Alzheimer-type dementia
The US market for Memantine Hydrochloride Tablets USP, 5 mg and 10 mg is around $60 million. The product will be manufactured at the company’s flagship facility at Bangalore and marketed by Strides Pharma Inc in the US Market. The product will be launched immediately.
Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.
